Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255083 | 0.97 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL8688535 | 0.97 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL8688500 | 0.97 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3836906 | 0.92 | — | — | |
| SCHEMBL823000 | 0.85 | — | — | |
| SCHEMBL16440537 | 0.85 | LMNA (0.34) | LMNAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL7784473 | 0.83 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL11808518 | 0.82 | TSHR (0.41) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL20483089 | 0.82 | — | — | |
| SCHEMBL9284273 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743269-B1 | PIM KINASE INHIBITOR, PREPARATION METHOD AND USE THEREOF IN DRUG PREPARATION | JIKAI BIOSCIENCES INC (CN) | 2018-09-26 | — | — | EP | disclosed |
| EP-2743271-B1 | PIM KINASE INHIBITORS AND PREPARATION METHOD AND USE IN MEDICINAL MANUFACTURE THEREOF | JIKAI BIOSCIENCES INC (CN) | 2017-05-31 | — | — | EP | disclosed |
| US-9090594-B2 | PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-9073885-B2 | Vitamin D3 lactone derivatives | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8969584-B2 | PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2015-03-03 | — | — | US | disclosed |
| EP-1589009-B1 | VITAMIN D3 LACTONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2743269-A1 | PIM KINASE INHIBITOR, PREPARATION METHOD AND USE THEREOF IN DRUG PREPARATION | Jikai Biosciences Inc. (CN) | 2014-06-18 | — | — | EP | disclosed |
| EP-2743271-A1 | PIM KINASE INHIBITOR AND PREPARATION METHOD AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences Inc. (CN) | 2014-06-18 | — | — | EP | disclosed |
| US-20140162999-A1 | PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140162998-A1 | PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20060148768-A1 | Vitamin d3 lactone derivatives | TEIJIN LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1589009-A1 | VITAMIN D3 LACTONE DERIVATIVE | Teijin Pharma Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162999-A1 | PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | SMN1; SMN2 4410/4885LMNA 2578/4885ALDH1A1 1370/4885 |
| US-20060148768-A1 | Vitamin d3 lactone derivatives | VDR, CYP24A1, CYP2R1 | SMN1; SMN2 4522/4885LMNA 399/4885ALDH1A1 2285/4885 |
| US-20140162998-A1 | PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | SMN1; SMN2 4516/4885LMNA 2612/4885ALDH1A1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.